newsfilter
← Latest News
GlobeNewswire·

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cashIn May 2025, Alzamend dosed the first